Pregnant Women
Conditions
Brief summary
From April 2021 to December 2021, 45 pregnant women who received intro fertilization-embyro transfer (IVF-ET) were recuited. According to their own wishes, 28 of them took Chinese medicine from the 2nd week after embryo transfer (intervention group), while the remaining 17 did not intake Chinese medicine (control group). Blood and feces samples were collected in the early morning of the 4th week after embryo transfer to detect 16S DNA sequences in feces, plasma metabolites, and whole blood transcriptomics.
Detailed description
Investigators planned to performed a observational clinical trial to determine the effects of the Chinese medicine (Gushen Antai recipe) including mainly Rehmannia glutinosa used in pregnant women for fetal protection. Two groupswere recruited, Chinese medicine intervention group and control group without Chinese medicine. In the 4th week after embryo transfer, blood and fetal were sampled for metabolic and intestinal microbiota analysis.
Interventions
COMBINATION_PRODUCTFetal Protection Pill
A Chinese medicine used in pregnant women for fetal protection, including mainly Rehmannia glutinosa.
Sponsors
Shanghai Institute of Palnned parenthood research
Shanghai Meiji Health Science and Technology Co., Ltd.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
* recieved IVF * childbirth without miscarriage * taking vitamins during pregnancy
Exclusion criteria
* miscarrige * missed sampling in the fourth week of pregnancy * not appropriate judged by the doctor
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 16s DNA analysis in feces | the fourth week in early pregnancy | intestinal flora analysis in patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| plasma metabonomics analysis by GC/LC mass | the fourth week in early pregnancy | plasma metabolic analysis in patients |
Other
| Measure | Time frame | Description |
|---|---|---|
| whole blood transcriptomics analysis by RNA sequencing | the fourth week in early pregnancy | blood transcriptomic analysis in patients |
Countries
China
Outcome results
None listed